Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II
- PMID: 9634475
- DOI: 10.1007/s002510050411
Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II
Abstract
The lymphocyte activation gene-3 (LAG-3), a major histocompatibility complex (MHC) class II ligand evolutionarily related to CD4, is expressed exclusively in activated T and NK lymphocytes and seems to play a role in regulating the evolving immune response. We first determined that surface LAG-3 expression on activated human T cells is upregulated by certain cytokines (IL-2, IL-7, IL-12) and not by others (IL-4, IL-6, IL-10, TNF-alpha, TNF-beta, IFN-gamma). Surface LAG-3 expression correlated with intracellular IFN-gamma production in both CD4+ and CD8+ T-cell subsets. We then analyzed the 5' transcription control sequences of LAG-3. A DNase I hypersensitive site induced in T cells following cellular activation was found in the region including the transcriptional start site, showing that DNA accessibility is a mechanism which restricts LAG-3 expression to activated T cells. Transcription is initiated at three sites. A GC box, 80 base pairs (bp) upstream of the major transcription start site, forms a minimal promoter which is regulated by two upstream regions containing positive and negative regulatory elements with multiple protein binding sites as shown by footprinting analysis. In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements. Finally, a 100 bp region downstream of the transcription start site was shown to be involved in the cell-specific control of LAG-3 expression. Understanding this highly regulated expression may help to determine the intriguing role of this activation-induced MHC class II ligand.
Similar articles
-
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9. doi: 10.1073/pnas.94.11.5744. Proc Natl Acad Sci U S A. 1997. PMID: 9159144 Free PMC article.
-
Lymphocyte activation gene-3 (LAG-3) expression and IFN-gamma production are variably coregulated in different human T lymphocyte subpopulations.J Immunol. 1998 Jul 1;161(1):489-93. J Immunol. 1998. PMID: 9647260
-
T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding.Eur J Immunol. 1996 May;26(5):1180-6. doi: 10.1002/eji.1830260533. Eur J Immunol. 1996. PMID: 8647185
-
Porcine T lymphocytes and NK cells--an update.Dev Comp Immunol. 2009 Mar;33(3):310-20. doi: 10.1016/j.dci.2008.06.003. Epub 2008 Jul 2. Dev Comp Immunol. 2009. PMID: 18601948 Review.
-
Aetiopathogenesis of autoimmune hepatitis.World J Gastroenterol. 2008 Jun 7;14(21):3306-12. doi: 10.3748/wjg.14.3306. World J Gastroenterol. 2008. PMID: 18528928 Free PMC article. Review.
Cited by
-
Induction of Inhibitory Receptors on T Cells During Plasmodium vivax Malaria Impairs Cytokine Production.J Infect Dis. 2015 Dec 15;212(12):1999-2010. doi: 10.1093/infdis/jiv306. Epub 2015 May 27. J Infect Dis. 2015. PMID: 26019284 Free PMC article.
-
Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells.J Neuroinflammation. 2015 Mar 15;12:52. doi: 10.1186/s12974-015-0273-0. J Neuroinflammation. 2015. PMID: 25880134 Free PMC article.
-
High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.J Mol Diagn. 2010 May;12(3):328-34. doi: 10.2353/jmoldx.2010.090100. Epub 2010 Mar 12. J Mol Diagn. 2010. PMID: 20228263 Free PMC article.
-
First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors.Br J Cancer. 2025 Jun;132(10):905-912. doi: 10.1038/s41416-025-02990-x. Epub 2025 Apr 15. Br J Cancer. 2025. PMID: 40234667 Free PMC article. Clinical Trial.
-
Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy.Clin Cancer Res. 2023 Mar 1;29(5):835-837. doi: 10.1158/1078-0432.CCR-22-3312. Clin Cancer Res. 2023. PMID: 36534010 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous